Mukesh Ambani-owned Reliance Life Sciences' COVID-19 vaccine — here's all we know so far
Reliance Life Scienceshas reportedly approached India’s drug regulator, seeking permission for trials of its vaccine.
- The subject expert committee (SEC) is said to have reviewed its application yesterday and gave its approval.
- Phase-1 of the trial usually lasts for 58 days to determine the highest dose that most patients can tolerate.
Indian pharma firm Reliance Life Sciences on Thursday, August 26, reportedly received regulatory approval to conduct clinical trials of its
View all Offers
View all Offers
- 56% OFF
SanDisk Ultra microSD UHS-I Card 128GB, 120MB/s R₹ 1199₹ 1199Buy On
- 16% OFF
2020 Apple iPad Air with A14 Bionic chip (10.9-inch/27.69 cm, Wi-Fi + Cellular, 256GB) - Space Grey (4th Generation)₹ 69900₹ 69900Buy On
- 38% OFF
Lenovo Legion 5 11th Gen Intel Core i7 15.6"(39.62cm) FHD IPS Gaming Laptop (16GB/512GB SSD/NVIDIA RTX 3050 4GB/120Hz Refresh Rate/Windows 10/MS Office/Backlit Keyboard/Phantom Blue/2.4Kg), 82JK007WIN₹ 110490₹ 110490Buy On
- 21% OFF
HP Envy x360 4th Gen AMD Ryzen 7 4700U 13.3 inches FHD Convertible Touchscreen Laptop (16GB RAM/1TB SSD/1000 Nits/Windows 10 Home/MS Office/Finger Print Reader/1.3 Kg), 13-ay0508AU, Black₹ 92490₹ 92490Buy On
- 34% OFF
Seagate Expansion 4TB Desktop External HDD - 8.89 cm (3.5 Inch) USB 3.0 for Windows and Mac with 3 yr Data Recovery Services, Portable Hard Drive (STKP4000400)₹ 7014₹ 7014Buy On
The company — run by India’s richest man
The subject expert committee (SEC) is said to have reviewed its application on Thursday and has given its approval.
AdvertisementReliance Life Sciences aims to obtain reliable information on safety, tolerability, how it reacts with living organisms (pharmacokinetics or PK) and mechanism of action of the drug. The company aims to determine the maximum tolerated dose (MTD) with these trials.
Business Insider has reached out to Reliance Life Sciences seeking more details about their vaccine and Phase-1 trials.
A person aware of the development told the publication that Phase-1 of the trial usually lasts for 58 days to determine the highest dose that most patients can tolerate. The company will be able to conduct phase two or three of the vaccine only after phase one is completed, the person told ET.
The vaccine by Reliance Life Sciences will be a recombinant protein vaccine, similar to the Corbevax vaccine developed by Hyderabad-based Biological E. Biological E is expected to apply for an emergency use authorisation (EUA), which allows temporary use of a medicine under specific conditions.
So far, six vaccines have received EUA in India. This includes Zydus Cadila’s vaccine, Serum Institute of India’s
Drugs Controller General of India (DCGI) had approved Cadila Healthcare’s ZyCoV-D COVID-19 vaccine for emergency use, earlier this week. ZyCoV-D vaccine is also suitable for the younger population above 12 years of age. Adding to it, the vaccine is needle-free unlike other vaccines.
AdvertisementThe company plans to manufacture 10-12 crore doses of ZyCoV-D annually and is expected to be made available in September in India.
Infosys, Wipro, Adani Green and other top stocks to watch out for on August 27
Google-backed Dunzo earned nearly ₹600 crore from 8 cities in FY21, CEO says they'll start expanding now
AdvertisementAmazon, Twitter, Hyundai, and Domino’s are buying Indian software fuelling a $75 billion dream chased by top VCs like Sequoia and Tiger Global
Popular on BI
- EXCLUSIVE: CoinDCX plans to hire more than 2,000 people this year — and they are not just looking at coders
- Amazon Sale 2022: Deals and offers on daily essential products
- Reliance Retail buys 54% stake in robotics firm Addverb Tech for $132 million
- Amazon Great Republic Day Sale 2022 – best deals on smartwatches and fitness bands
- After Maruti, now Tata Motors raises car prices marginally